Braveheart Bio, a clinical-stage biotechnology company, is targeting a $318.8 million US initial public offering. The company filed for a Nasdaq listing under the ticker BRVE on July 14, 2026. This IPO aims to secure funding for the advanced Phase 3 testing of its lead drug candidate, BHB-1893, an oral cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy (HCM).
The proceeds from the IPO will primarily be allocated to advancing BHB-1893 through global Phase 3 trials. Specifically, Braveheart plans to initiate a Phase 3 study for obstructive hypertrophic cardiomyopathy (oHCM) in the second half of 2026, and another for non-obstructive HCM (nHCM) in the first half of 2027. Clinical operations, regulatory expenses, program management, and general corporate purposes will also be supported by the raised capital.
Braveheart Bio is a spin-off from Hengrui, a prominent Chinese drug developer. Braveheart secured exclusive rights to BHB-1893 outside Greater China through a $65 million upfront payment and a potential $1 billion biobuck deal in 2025. Hengrui retains an 11.3% stake in Braveheart. Key backers of Braveheart include Forbion (27.8%), OrbiMed (15.6%), and a16z Bio + Health (13.9%), which also contributed to a $185 million launch round in November. Travis Murdoch, the CEO of Braveheart, previously sold HI-Bio to Biogen for $1.15 billion upfront in 2024, and Biogen CEO Chris Viehbacher serves as Braveheart's board chair. Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor are the lead underwriters for the IPO.
BHB-1893 is poised to compete with existing and emerging treatments for HCM, including Camzyos and Myqorzo, which are approved for oHCM. While Bristol Myers Squibb's drug failed in nHCM, Cytokinetics' drug recently succeeded in that setting in May. Braveheart's strategy emphasizes differentiating BHB-1893 through a potentially faster onset, lower "LVEF cost," predictable pharmacokinetics without major CYP liabilities, and simplified titration to enhance real-world adoption. Braveheart aims to mirror the independent success of companies like Cytokinetics in the biotech sector.
